Novartis: progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

 

• Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received first line treatment with Lutathera® in combination with long-acting octreotide, versus high-dose long-acting octreotide alone1,2

• Lutathera is the first radioligand therapy (RLT) to demonstrate clinically meaningful benefit in a first line setting1

• Findings to be presented at an upcoming medical meeting and discussed with regulatory authorities, with submissions to follow

• Novartis is investigating a broad portfolio of RLTs, exploring their treatment potential in a range of advanced cancers beyond prostate and GEP-NET, including lung, breast, pancreatic and colon. The company also continues to support the increasing demand for RLTs with expansions at existing manufacturing sites in the U.S. and Europe and a new state-of-the-art facility in Indianapolis, U.S., which is awaiting FDA approval

https://finance.yahoo.com/news/novartis-radioligand-therapy-lutathera-demonstrated-051700375.html